Research on vaccines and immunization. Covers COVID and flu vaccines, outbreak response, long-lasting antibodies, and vaccination in vulnerable groups.
Researchers have developed two COVID-19 vaccines that elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research. The Moderna mRNA vaccine and a protein-based vaccine candidate showed strong immunity in infant rhesus macaques, with no adverse effects.
A recent study found that daily COVID-19 testing in the NFL enabled early detection of infections, even among asymptomatic individuals. The study also revealed disparities in vaccination rates among healthcare workers, with lower rates among Black and Hispanic employees compared to their Asian and White counterparts.
Two studies demonstrate the impact of gender-neutral HPV vaccination on overall protection against HRHPV infections, even with low vaccination coverage. In Finland, communities with both boys and girls vaccinated saw a significant decrease in cervical HPV16/18 infections, including among unvaccinated women due to the herd effect.
Researchers at Brown University developed a new modeling approach that captures the impact of behavioral components on infectious disease transmission. The model accurately reproduces case rates throughout the pandemic in the US and individual states, providing valuable insights for forecasting future trends and scenarios.
Care home residents over 70 have a delayed and weaker immune response to vaccines compared to younger individuals, making them more susceptible to SARS-CoV-2 infections. This phenomenon has been confirmed by researchers from Charité - Universitätsmedizin Berlin.
A survey study among women with breast cancer in Mexico found a high hesitancy rate toward COVID-19 vaccination due to concerns about vaccine safety and efficacy. The study highlights the need for healthcare providers to address these concerns and improve access to vaccination services for this vulnerable population.
Research found that COVID-19 vaccines are safe for patients with inflammatory bowel disease (IBD), who experience chronic digestive symptoms. Most side effects were mild and short-lived, with gastrointestinal issues being the most common. IBD patients on biologic therapies reported even fewer side effects due to the modulating effect o...
A large study found that COVID-19 vaccines induce a strong immune response in patients with various types of cancer, with high seroconversion rates among solid tumor patients. However, those receiving treatments for blood cancers had lower but still significant rates, highlighting the importance of vaccination in vulnerable populations.
Researchers found that a single-shot COVID-19 vaccine generated strong immune responses against all SARS-CoV-2 variants. The study suggests non-neutralizing antibodies and T cell responses may contribute to protection against COVID-19, particularly in regions with variant prevalence.
Experts warn that India's current vaccination approach is causing huge numbers of avoidable deaths and is deeply inequitable. The government's focus on younger age groups has resulted in unequal access to vaccines, with rural areas and disadvantaged urban populations receiving limited coverage.
Scientists at McMaster University have developed a new treatment approach for people suffering from VITT, combining anti-clotting drugs with high doses of intravenous immunoglobulin. The treatment's effectiveness was shown in three Canadian patients who received the AstraZeneca vaccine and developed VITT.
A new study reveals that COVID-19 vaccination leads to strong T cell responses against the virus in all patients on dialysis, and nearly 58% of kidney transplant recipients. However, low antibody responses were observed in kidney transplant recipients, raising concerns about their protection from COVID-19.
A new Northwestern Medicine study found that routine check-ups have several health benefits, including better detection and treatment of chronic illnesses, increased vaccinations and screenings, and improved patient-reported outcomes. These benefits are particularly important for at-risk populations.
The Murdoch Children's Research Institute is conducting a global study to better understand COVID-19 variants and the effectiveness of vaccines in preventing their spread. The BRACE trial, funded by the Bill & Melinda Gates Foundation, investigates biomarkers that indicate protection against COVID-19 infection.
Dr. Katalin Karikó's groundbreaking research on modifying nucleosides in mRNA led to the development of mRNA vaccines with over 94% efficacy against COVID-19. The Vilcek Prize for Excellence recognizes her contributions to science and medicine.
Researchers have developed a technology to manipulate viruses synthetically, allowing for rapid analysis and mapping of new potential virus variants. This innovation enables scientists to mimic natural selection processes safely in a controlled laboratory environment.
A new vaccine called KCONVAC has been shown to be safe and induce antibody production in healthy Chinese adults. The phase 1 and 2 clinical trials demonstrated that the vaccine is well-tolerated and generates a robust immune response, with stronger antibody production seen when participants received their second dose four weeks apart.
A study of UK dental care professionals found that natural infection alone is unlikely to generate meaningful, durable herd immunity, emphasizing the importance of vaccinations. The data also suggest that previous infection with SARS-CoV-2 leads to a faster and stronger immune response following vaccination.
Researchers at ETH Zurich developed a vaccine that guides bacteria's evolution to make them a weaker pathogen, rather than trying to kill them. The combination vaccine was shown to be more effective in preventing Salmonella infections than existing vaccines.
A study of over 1,500 UK dental professionals found 16.3% had SARS-CoV-2 antibodies, highlighting the occupational risk of infection. The study also showed ethnicity was a significant risk factor and that COVID-19 vaccination provided rapid and high antibody responses.
A five-pronged strategy addressing behavioural and socio-demographic factors is proposed to combat vaccine hesitancy. Confidence in vaccine safety is crucial, while addressing complacency among younger people and those of lower socioeconomic status is essential for increased uptake.
A Phase 1/2 clinical trial has begun at the NIH to assess the safety and immunogenicity of different COVID-19 vaccine booster regimens. Participants will receive a single booster dose of the Moderna COVID-19 vaccine, followed by telephone check-ins and in-person follow-up visits for one year.
A mathematical simulation by researchers at UNC Health Care shows that non-pharmaceutical interventions like mask-wearing and physical distancing can help prevent COVID-19 spikes as vaccines are distributed. The study found that widespread vaccine adherence and adherence to precautions can lead to a sustained decline in new cases.
Researchers investigated mRNA vaccination response in Israeli cancer patients. Patients with cancer who received the vaccine showed seropositivity, indicating an immune response against SARS-CoV-2. The study aimed to assess the safety and efficacy of mRNA vaccines in this vulnerable population.
Researchers developed a DNA vaccine encoding SARS-CoV-2 spike protein, which induced long-lasting antibodies in mice and hamsters. The vaccine showed protective efficacy against COVID-19 infection in hamsters, with no loss of body weight or viral RNA in their lungs.
A survey study explores associations between race/ethnicity, medical mistrust and willingness to receive COVID-19 vaccines. The study found that racial/ethnic group-based medical mistrust is a significant factor in vaccine hesitancy.
A comprehensive review suggests that gut microbiota play a crucial role in immune responses to vaccinations. The study aims to improve vaccine effectiveness by understanding the microbiota's impact on B and T cell immune responses.
A new Finnish study reveals pertussis is more prevalent among middle-aged adults in European countries than previously assumed, leading to concerns about underdiagnosed cases. The study also highlights the low levels of antibodies against diphtheria, indicating decreasing herd immunity.
Scientists from Scripps Research have discovered a cross-reactive coronavirus antibody that neutralizes SARS-CoV-1 and other coronaviruses, including those causing the common cold. The finding is a promising development for the eventual development of a pan-coronavirus vaccine.
A recent investigation by The BMJ found that vaccine advisory committees in the US and UK have different disclosure standards, leaving the public uncertain about experts' industry ties. Experts on these committees rarely disclose conflicts of interest, despite significant financial payments from pharmaceutical companies.
A study using real-world air traffic control data found that vaccination programs alone may not stop the ongoing second wave of COVID-19 infections in the US. Strict social distancing measures remain necessary to prevent a new wave, according to researchers.
Researchers analyzed state health department COVID-19 vaccine website accessibility and usability, finding challenges that create frustration and contribute to ineffective vaccination efforts. The study highlights the need for improved accessibility and usability in healthcare websites to promote equitable health outcomes.
A new study by Brigham and Women's Hospital uses an ultrasensitive test to detect circulating antigen in vaccinated individuals, showing a strong immune response. The test found evidence of low viral protein levels followed by antibody production and clearance of proteins from the blood.
Researchers analyzed COVID-19 swab samples from California counties and found the new variant was more transmissible, infecting people who already had COVID-19. Vaccines showed higher neutralization rates against the variant than antibodies from previously infected patients.
A small case series found that vaccination was not linked to worsening symptoms or reduced quality of life in patients with persistent COVID-19 symptoms. The study included 163 patients who received one dose of either Pfizer-BioNTech or Oxford-AstraZeneca vaccine.
The University of Illinois Chicago is leading a multi-center collaborative to improve community vaccinations, testing, and engagement in clinical research. The Chicagoland COVID Collaborative aims to bolster COVID-19 vaccine confidence and access among Black and Latino communities.
A retrospective cohort study found that autonomous cortisol secretion is associated with a 2- to 3-fold increased risk of death and cardiovascular disease in patients with adrenal incidentalomas. Researchers recommend treating known cardiovascular risk factors and incorporating findings into treatment decisions, including surgery.
A national study found nearly 90,000 people taking immunosuppressive drugs, including steroids, may have a slower or weaker response to COVID-19 vaccines. Researchers are exploring strategies to improve vaccine efficacy in this vulnerable population.
Research by MSU's Morteza Mahmoudi suggests that Covid-19 vaccines developed with nanomedicine may have different efficacies for men and women due to sex-based differences. The study highlights the importance of considering sex in vaccine development and research, particularly in using nanomedicines.
A new study reveals key details of how SARS-CoV-2 variants escape the immune response created by natural infection or vaccination. The research highlights that several mutations are clustered in one site on the spike protein, disrupting antibody binding and neutralization.
Researchers are studying the effectiveness and safety of COVID-19 vaccines during pregnancy, using data from Ontario's vaccination registry and province-wide birth registry. The study aims to inform decision-making for ongoing COVID-19 vaccine administration programs in Canada.
A retrospective study found increased axillary lymph node uptake on PET scans after COVID-19 vaccination, affecting 7.4% of FDG and 23.1% of 11C-choline PET examinations. Ipsilateral deltoid uptake was also observed in 14.5% of examinations.
Researchers developed a microparticle-based cancer vaccine that kickstarts an immune response, increasing the proportion of mice cured of tumors to 75%. Combining the vaccine with immune checkpoint inhibitors greatly improves treatment success, offering a promising approach to improving cancer treatment.
A recent study published in PLOS ONE found that individuals relying on traditional news sources are more accepting of the COVID-19 vaccine. The research highlights the importance of trusted sources in shaping public opinion on vaccination.
Developed by Inserm teams and French company NEOVACS, the conjugate vaccine induces sustained production of antibodies against IL-4 and IL-13, significantly reducing asthma symptoms.
Researchers have successfully treated a patient with vaccine-induced thrombotic thrombocytopenia (VITT) using intravenous immunoglobulin concentrates, cortisone, and specific anticoagulants. Prompt diagnosis and treatment can prevent life-threatening thrombosis.
Researchers have discovered a misinterpreted model of immature flavivirus particles, revealing an unexpected organisation that could lead to new and better vaccines. The study's findings define the exact wiring of the immature virus before it becomes infectious, providing a solid foundation for designing tomorrow's treatments.
A new study examines the safety of COVID-19 vaccines in patients with cancer, providing insights into potential risks and benefits. The research found that while some cancer treatments may interact with COVID-19 vaccines, the overall risk is low.
A UCR study found that messages stressing the Christian doctrine of 'love thy neighbor' and aligning mask-wearing with patriotism can effectively persuade white evangelicals to wear masks. The research also suggests that similar messaging could be used for pro-vaccine efforts, particularly targeting Republican-leaning individuals.
Researchers recommend surveillance, accurate diagnosis, and rapid response to counteract COVID-19 misinformation and disinformation. They also introduce a taxonomy of categories for different types of misinformation related to Covid-19 and vaccination.
A new COVID-19 vaccine developed using the Sementis Copenhagen Vector (SCV) platform is being accelerated for human clinical trials within 18 months. The vaccine aims to provide long-term and broad-ranging immunity against SARS-CoV-2, including mutant strains.
A new study from Beth Israel Deaconess Medical Center found that COVID-19 mRNA vaccines triggered immune responses in pregnant and lactating women, with maternal antibodies transferred to infant cord blood and breast milk. This suggests that vaccinating pregnant mothers may protect infants from COVID-19 infection.
Researchers at Scripps Research have unveiled an innovative Ebola virus vaccine design that stimulates a better protective immune response. The new approach involves tethering copies of the Ebola virus outer spike protein to a spherical carrier particle, resulting in a more stable and realistic-looking virus particle.
A new UNSW Sydney study examines content between December 2019 to November 2020 and found over 103 million people globally shared or reacted with misinformation about COVID-19 vaccines. The study highlights the need for traditional risk communication and community engagement methods to counter misinformation.
Research from the Com-COV study shows that mixing COVID-19 vaccine doses can lead to more frequent mild-moderate symptoms, but adverse reactions are short-lived and no safety concerns were found. The study's findings suggest that mixed schedules could result in increased work absences after vaccination.
A dengue virus vaccine candidate has produced a protective immune response in infected mice, offering a promising alternative to existing vaccines. The UQ-developed vaccine uses an Australian insect virus and can be administered via a microarray patch for easy, needle-free delivery.
A new study by Stanford researchers found that nearly two-thirds of California prison residents who were offered a COVID-19 vaccine accepted at least one dose. Acceptance rates varied across different racial and ethnic groups, with Hispanic and white inmates having the highest acceptance rates.
A US study suggests that delaying the second dose of COVID-19 vaccines for people under 65 could result in lower mortality rates, with estimates suggesting a 20% reduction in deaths. The strategy is optimal when vaccine efficacy from one dose is 80% or higher and vaccination rates are low.
A study published in JAMA Dermatology reports delayed localized injection-site reactions to the Moderna COVID-19 vaccine in 16 patients. The authors highlight this finding as a potential side effect of the vaccine, emphasizing the importance of monitoring for such reactions.
A new Northwestern Medicine study of placentas from vaccinated patients found no evidence of injury, supporting the safety of COVID-19 vaccines in pregnancy. The study adds to growing evidence that vaccination can protect fetuses without increasing harm.